{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:34:30Z","timestamp":1792427670943,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T00:00:00Z","timestamp":1647993600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Genes & Diseases"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.gendis.2022.03.003","type":"journal-article","created":{"date-parts":[[2022,3,26]],"date-time":"2022-03-26T17:49:58Z","timestamp":1648316998000},"page":"1019-1028","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Durability of Hepatitis B surface antigen seroclearance in patients experienced nucleoside analogs or interferon monotherapy: A real-world data from Electronic Health Record"],"prefix":"10.1016","volume":"10","author":[{"given":"Zongqi","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huizhi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaomiao","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieli","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaosong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinjun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4890-192X","authenticated-orcid":false,"given":"Haijun","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1857-2798","authenticated-orcid":false,"given":"Quanxin","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2225-9550","authenticated-orcid":false,"given":"Ailong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.gendis.2022.03.003_bib1","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jhep.2019.11.003","article-title":"Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference","volume":"72","author":"Cornberg","year":"2020","journal-title":"J Hepatol."},{"issue":"10","key":"10.1016\/j.gendis.2022.03.003_bib2","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/jvh.13126","article-title":"Roadmap to functional cure of chronic hepatitis B: an expert consensus","volume":"26","author":"Ning","year":"2019","journal-title":"J Viral Hepat"},{"issue":"3","key":"10.1016\/j.gendis.2022.03.003_bib3","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S2468-1253(18)30308-X","article-title":"Spontaneous loss of surface antigen among adults living with chronic hepatitis B virus infection: a systematic review and pooled meta-analyses","volume":"4","author":"Zhou","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.gendis.2022.03.003_bib4","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1053\/j.gastro.2018.10.027","article-title":"Factors associated with rates of HBsAg seroclearance in adults with chronic HBV infection: a systematic review and meta-analysis","volume":"156","author":"Yeo","year":"2019","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.gendis.2022.03.003_bib5","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1002\/hep.31610","article-title":"Comparison of long-term clinical outcomes between spontaneous and therapy-induced HBsAg seroclearance","volume":"73","author":"Choi","year":"2021","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.gendis.2022.03.003_bib6","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jhep.2004.10.026","article-title":"Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance","volume":"42","author":"Ahn","year":"2005","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.gendis.2022.03.003_bib7","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1136\/gutjnl-2013-305785","article-title":"Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma","volume":"63","author":"Liu","year":"2014","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.gendis.2022.03.003_bib8","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"European association for the study of the liver, EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.gendis.2022.03.003_bib9","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s12072-017-9799-9","article-title":"Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update","volume":"11","author":"Omata","year":"2017","journal-title":"Hepatol Int"},{"issue":"1","key":"10.1016\/j.gendis.2022.03.003_bib10","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.gendis.2022.03.003_bib11","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1136\/gutjnl-2013-305517","article-title":"HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability","volume":"63","author":"Kim","year":"2014","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.gendis.2022.03.003_bib12","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1053\/j.gastro.2010.10.011","article-title":"Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B","volume":"140","author":"Heathcote","year":"2011","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.gendis.2022.03.003_bib13","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jhep.2012.11.039","article-title":"Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside\/nucleotide analogue therapy: finite treatment duration unlikely","volume":"58","author":"Chevaliez","year":"2013","journal-title":"J Hepatol"},{"issue":"9865","key":"10.1016\/j.gendis.2022.03.003_bib14","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.gendis.2022.03.003_bib15","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1053\/j.gastro.2012.05.039","article-title":"Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir","volume":"143","author":"Hadziyannis","year":"2012","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.gendis.2022.03.003_bib16","doi-asserted-by":"crossref","first-page":"7264","DOI":"10.4049\/jimmunol.0903490","article-title":"Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: a six-year follow-up study","volume":"186","author":"Tang","year":"2011","journal-title":"J Immunol"},{"issue":"9454","key":"10.1016\/j.gendis.2022.03.003_bib17","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(05)17701-0","article-title":"Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial","volume":"365","author":"Janssen","year":"2005","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.gendis.2022.03.003_bib18","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1053\/j.gastro.2008.05.031","article-title":"Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b","volume":"135","author":"Buster","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gendis.2022.03.003_bib19","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/1471-2334-11-165","article-title":"Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: a meta-analysis of controlled clinical trials","volume":"11","author":"Li","year":"2011","journal-title":"BMC Infect Dis"},{"issue":"26","key":"10.1016\/j.gendis.2022.03.003_bib20","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa043470","article-title":"Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B","volume":"352","author":"Lau","year":"2005","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.gendis.2022.03.003_bib21","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jhep.2017.09.018","article-title":"Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue-treated patients","volume":"68","author":"Yip","year":"2018","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.gendis.2022.03.003_bib22","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1002\/hep.29323","article-title":"Hepatitis B cure: from discovery to regulatory approval","volume":"66","author":"Lok","year":"2017","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.gendis.2022.03.003_bib23","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1365-2893.2009.01146.x","article-title":"Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-na\u00efve HBeAg-positive patients with chronic hepatitis B","volume":"17","author":"Gish","year":"2010","journal-title":"J Viral Hepat"},{"issue":"2","key":"10.1016\/j.gendis.2022.03.003_bib24","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.23327","article-title":"Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B","volume":"51","author":"Chang","year":"2010","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.gendis.2022.03.003_bib25","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.jhep.2009.01.016","article-title":"High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study","volume":"50","author":"Moucari","year":"2009","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.gendis.2022.03.003_bib26","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.cgh.2019.07.018","article-title":"Durability of spontaneous and treatment-related loss of hepatitis B s antigen","volume":"18","author":"Alawad","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.gendis.2022.03.003_bib27","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00699-19","article-title":"Electronic health informatics data to describe clearance dynamics of hepatitis B surface antigen (HBsAg) and e antigen (HBeAg) in chronic hepatitis B virus infection","volume":"10","author":"Downs","year":"2019","journal-title":"mBio"},{"issue":"2","key":"10.1016\/j.gendis.2022.03.003_bib28","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.cgh.2019.04.020","article-title":"Durability of interferon-induced hepatitis B surface antigen seroclearance","volume":"18","author":"Wu","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.gendis.2022.03.003_bib29","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1111\/jvh.12738","article-title":"HBsAg loss after peginterferon-nucleotide combination treatment in chronic hepatitis B patients: 5 years of follow-up","volume":"24","author":"Stelma","year":"2017","journal-title":"J Viral Hepat"},{"issue":"1","key":"10.1016\/j.gendis.2022.03.003_bib30","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/j.gastro.2015.09.043","article-title":"Combination of tenofovir disoproxil fumarate and peginterferon \u03b1-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B","volume":"150","author":"Marcellin","year":"2016","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.gendis.2022.03.003_bib31","doi-asserted-by":"crossref","first-page":"e1003613","DOI":"10.1371\/journal.ppat.1003613","article-title":"Alpha-interferon suppresses hepadnavirus transcription by altering epigenetic modification of cccDNA minichromosomes","volume":"9","author":"Liu","year":"2013","journal-title":"PLoS Pathog"},{"issue":"17","key":"10.1016\/j.gendis.2022.03.003_bib32","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00442-20","article-title":"Interferon alpha induces multiple cellular proteins that coordinately suppress hepadnaviral covalently closed circular DNA transcription","volume":"94","author":"Cheng","year":"2020","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.gendis.2022.03.003_bib33","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/hep.31282","article-title":"Functional comparison of interferon-\u03b1 subtypes reveals potent hepatitis B virus suppression by a concerted action of interferon-\u03b1 and interferon-\u03b3 signaling","volume":"73","author":"Chen","year":"2021","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.gendis.2022.03.003_bib34","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1002\/hep.29479","article-title":"Epigenetic regulation of hepatitis B virus covalently closed circular DNA: implications for epigenetic therapy against chronic hepatitis B","volume":"66","author":"Hong","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.gendis.2022.03.003_bib35","doi-asserted-by":"crossref","first-page":"103464","DOI":"10.1016\/j.ebiom.2021.103464","article-title":"Longitudinal characterization of phenotypic profile of T cells in chronic hepatitis B identifies immune markers associated with HBsAg loss","volume":"69","author":"Xiong","year":"2021","journal-title":"EBioMedicine"},{"issue":"5","key":"10.1016\/j.gendis.2022.03.003_bib36","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/hep.24555","article-title":"Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C","volume":"54","author":"Liaw","year":"2011","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.gendis.2022.03.003_bib37","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/hep4.1436","article-title":"Durability of hepatitis B surface antigen loss with nucleotide analogue and peginterferon therapy in patients with chronic hepatitis B","volume":"4","author":"Lok","year":"2019","journal-title":"Hepatol Commun"},{"issue":"2","key":"10.1016\/j.gendis.2022.03.003_bib38","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/hep.29082","article-title":"Role of surface antibody in hepatitis B reactivation in patients with resolved infection and hematologic malignancy: a meta-analysis","volume":"66","author":"Paul","year":"2017","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1016\/j.gendis.2022.03.003_bib39","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/jvh.13151","article-title":"Predictors of sustained functional cure in hepatitis B envelope antigen-negative patients achieving hepatitis B surface antigen seroclearance with interferon-alpha-based therapy","volume":"26","author":"Li","year":"2019","journal-title":"J Viral Hepat"},{"issue":"7","key":"10.1016\/j.gendis.2022.03.003_bib40","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1111\/liv.14801","article-title":"Outcome of Chinese patients with hepatitis B at 96 weeks after functional cure with IFN versus combination regimens","volume":"41","author":"Pan","year":"2021","journal-title":"Liver Int"},{"issue":"5","key":"10.1016\/j.gendis.2022.03.003_bib41","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41571-019-0167-7","article-title":"Real-world data: towards achieving the achievable in cancer care","volume":"16","author":"Booth","year":"2019","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Genes & Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352304222000563?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352304222000563?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T17:31:14Z","timestamp":1762450274000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352304222000563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S2352304222000563"],"URL":"https:\/\/doi.org\/10.1016\/j.gendis.2022.03.003","relation":{},"ISSN":["2352-3042"],"issn-type":[{"value":"2352-3042","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Durability of Hepatitis B surface antigen seroclearance in patients experienced nucleoside analogs or interferon monotherapy: A real-world data from Electronic Health Record","name":"articletitle","label":"Article Title"},{"value":"Genes & Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gendis.2022.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co., Ltd.","name":"copyright","label":"Copyright"}]}}